ArticleJSES international2023
The incidence of shoulder arthroplasty infection presents a substantial economic burden in the United States: a predictive model.
Article in JSES international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 29 citations in OpenAlex.
- Pre-operative antiplatelet therapy is associated with increased risk of periprosthetic joint infection following total shoulder arthroplasty.Journal of shoulder and elbow arthroplasty · 2026Article
- The impact of noninfective enteritis and colitis on outcomes following shoulder arthroplasty: a propensity-matched retrospective cohort study of 8,574 patients.JSES international · 2026Article
- Current practices of infection prevention for primary shoulder arthroplasty: A survey of American Shoulder and Elbow Surgeons Society members.Bulletin of the Hospital for Joint Disease (2013) · 2026Article
- Assessment of a painful shoulder arthroplasty.Journal of clinical orthopaedics and trauma · 2025Article
- How does residency program reputation influence American shoulder and elbow surgeons fellowship match results?JSES reviews, reports, and techniques · 2025Article
- Perioperative Management, Complications, and Outcomes of Shoulder Arthroplasty in Patients with Diabetes Mellitus.JBJS reviews · 2025Review
- Reverse versus anatomic total shoulder arthroplasty: A large matched cohort analysis.Journal of orthopaedics · 2024Article
- Efficacy of a Novel Intraoperative Surgical Irrigant in Preventing Periprosthetic Joint Infections in Primary Knee, Hip, and Shoulder Arthroplasties: A Retrospective Analysis.Orthopaedic surgery · 2024Article
- Do Preoperative Corticosteroid Injections Increase the Risk of Infection after Shoulder Arthroscopy or Shoulder Arthroplasty? A Systematic Review.Healthcare (Basel, Switzerland) · 2024Review
- Predictors of Higher Costs Following Reverse Total Shoulder Arthroplasty.The archives of bone and joint surgery · 2024Article
- Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection.BMC infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Periprosthetic joint infections (PJIs) are a major cause of morbidity after shoulder arthroplasty. Prior national database studies have estimated the trends of shoulder PJI up to 2012. Methods: The Nationwide Inpatient Sample database was queried for primary and revision anatomic total shoulder arthroplasty, reverse total shoulder arthroplasty, and hemiarthroplasty from 2011-2018. Multivariate regression was used to predict cases and charges through the year 2030 adjusted to 2021 purchasing power parity. Results: From 2011 to 2018, PJI was found to be 1.1% shoulder arthroplasties, from 0.8% (2011) to 1.4% (2018). Anatomic total shoulder arthroplasty experienced the greatest proportion of infections at 2.0%, followed by hemiarthroplasty at 1.0% and reverse total shoulder arthroplasty at 0.3%. Total hospital charges grew 324%, from $44.8 million (2011) to $190.3 million (2018). Our regression model projects 176% growth in cases and 141% growth in annual charges by 2030. Conclusion: This study demonstrates the large economic burden that shoulder PJIs pose on the American healthcare system, which is predicted to reach nearly $500 million in charges annually by 2030. Understanding trends in procedure volume and hospital charges will be critical in evaluating strategies to reduce shoulder PJIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.